Nexentis Technologies Inc.

Nexentis Technologies is a drug discovery company focused on therapeutics for cancer and inflammatory metabolic diseases, also investing in renewable energy projects.

Health Tech & Life Sciences
Active
Public Ness Ziona, Israel Founded 2009
Last updated 2026-11-05
Total raised
$4.2M
Last: PIPE 2026-06
Stage
Public
Founded
2009
Headcount
8
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences

About

Nexentis Technologies Inc. is a Nasdaq-listed operating company that primarily focuses on biotechnology drug discovery through its wholly-owned subsidiary, MitoCareX Bio Ltd.. MitoCareX Bio is dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways using its proprietary MITOLINE™ algorithm platform. Additionally, Nexentis invests in European renewable energy assets, specifically solar projects, using a "Ready to Build" (RTB) business model.

Funding history · 2 rounds · $4.2M total

2 events/rounds · $4.2M Total Funding: $4.2M in Public Equity
Jun 2026
Public Offering $1.3M stocktitan.net ↗
Jun 2026
Public Offering $2.9M sec.gov ↗

Acquisitions · 1

Oct 2025
MitoCareX Bio Ltd. Undisclosed

Offices

Ness Ziona, Israel · HQ / main office

Q&A

What is Nexentis Technologies Inc.'s primary business focus?
Nexentis Technologies Inc. is a Nasdaq-listed operating company primarily focused on biotechnology drug discovery through its wholly-owned subsidiary, MitoCareX Bio Ltd. Additionally, Nexentis invests in European renewable energy assets, specifically solar projects.
When was Nexentis Technologies Inc. founded and where is it headquartered?
Nexentis Technologies Inc. was founded in 2009 and is headquartered in Ness Ziona, Israel.
What is the total amount of funding Nexentis Technologies Inc. has raised?
Nexentis Technologies Inc. has raised a total of $4,150,000.
What was Nexentis Technologies Inc.'s most recent funding round?
In June 2026, Nexentis Technologies Inc. completed a Public Offering (PIPE) that raised $1,250,000.
Which company did Nexentis Technologies Inc. acquire?
Nexentis Technologies Inc. acquired MitoCareX Bio Ltd. in October 2025.
How many employees does Nexentis Technologies Inc. have?
Nexentis Technologies Inc. has 1-10 employees.
Who is the CEO of Nexentis Technologies Inc.?
David Palach serves as the Chief Executive Officer of Nexentis Technologies Inc.
What is the focus of Nexentis Technologies Inc.'s subsidiary, MitoCareX Bio Ltd.?
MitoCareX Bio Ltd. is dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways using its proprietary MITOLINE™ algorithm platform.

Team · 5

David Palach
Chief Executive Officer
Dr. Alon Silberman
Chief Executive Officer of MitoCareX Bio
Shlomo Zakai
Controller
Amitay Weiss
Director
Prof. Dan T. Major
Scientific Advisory Board, MitoCareX Bio Ltd.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Technologies

Highlights

Climate TechPatents
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitewww.nexentistech.com

Identifiers & details

Founded2009
Employees (exact)8

Acquisitions & public offerings

AcquiredDateAmount
MitoCareX Bio Ltd.2025-10